SUMMARY
Gama-butyrolactone (GBL) is an easily accessible and inexpensive recreational drug popular primarily in night clubs. GBL is a precursor of the endogenous neurotransmitter gamma-hydroxybutyrate (GHB), which acts as an agonist at the GABAB and GHB receptors in the central nervous system (CNS). Low doses inhibit dopamine release, resulting in euphoric effects and reduced central inhibition. Higher doses stimulate the secretion of opioid-like substances and rapidly depress CNS. Addiction develops after several weeks to months of everyday usage. The clinical features of withdrawal are in principle similar to those of ethanol and/or benzodiazepine withdrawal. This paper presents the case of GBL withdrawal syndrome, which was clinically manifested with developed delirium, confusion, hallucinations, and agitation. Therapeutic management include high doses of benzodiazepines and, if needed, barbiturates, anticonvulsive and antipsychotic drugs.